Sugi Predict

Sugi Predict / Compounds / SCHEMBL1481174

SCHEMBL1481174

SCHEMBL1481174

CCOc1ccc(-c2ccc(C=Cc3nc(-c4ccc(Cl)cc4Cl)cn3Cc3ccc(C(=O)O)cc3)cc2)cc1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SMN1; SMN2 Q16637 2/20 0.43
▸ KDM4E B2RXH2 2/20 0.43
▸ NPC1 O15118 1/20 0.43
▸ CRHBP P24387 1/20 0.43
▸ RAB9A P51151 1/20 0.43
▸ CRHR2 Q13324 1/20 0.43
▸ MAOB P27338 2/20 0.41
▸ CSNK2A2 P19784 2/20 0.38
▸ CSNK2B P67870 2/20 0.38
▸ CSNK2A1 P68400 2/20 0.38
▸ CSNK2A3 Q8NEV1 1/20 0.38
▸ CHRNA7 P36544 2/20 0.38
▸ NR4A2 P43354 1/20 0.38
▸ SRD5A2 P31213 2/20 0.38
▸ PTPN11 Q06124 1/20 0.38
▸ HCRTR1 O43613 1/20 0.38
▸ HCRTR2 O43614 1/20 0.38
▸ KCNA3 P22001 1/20 0.38
▸ ENPP2 Q13822 1/20 0.38
▸ TP53 P04637 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1481171 1.00 SMN1; SMN2 (0.43) SMN1; SMN2KDM4ENPC1CRHBPRAB9A
SCHEMBL1481424 0.94 RARB (0.42) SMN1; SMN2KDM4ENPC1CRHBPRAB9A
SCHEMBL1481425 0.94 RARB (0.42) SMN1; SMN2KDM4ENPC1CRHBPRAB9A
SCHEMBL1480807 0.92 DRD2 (0.46) SMN1; SMN2NPC1RAB9AMAOBCHRNA7
SCHEMBL1480805 0.92 DRD2 (0.46) SMN1; SMN2NPC1RAB9AMAOBCHRNA7
SCHEMBL1676193 0.89 KDM4E (0.42) SMN1; SMN2KDM4ENPC1CRHBPRAB9A
SCHEMBL1480524 0.89 NR4A2 (0.44) SMN1; SMN2KDM4ENPC1CRHBPRAB9A
SCHEMBL1480521 0.89 NR4A2 (0.44) SMN1; SMN2KDM4ENPC1CRHBPRAB9A
SCHEMBL1676197 0.89 KDM4E (0.42) SMN1; SMN2KDM4ENPC1CRHBPRAB9A
SCHEMBL1481887 0.89 CNR1 (0.45) SMN1; SMN2KDM4ENPC1CRHBPRAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110092553-A1 Substituted Azole Derivatives, Compositions, and Methods of Use TRANSTECH PHARMA, INC. (US) 2011-04-21 — — US disclosed
US-20110077399-A1 Substituted Azole Derivatives as Therapeutic Agents TRANSTECH PHARMA, INC. (US) 2011-03-31 — — US disclosed
WO-2004071447-A9 SUBSTITUTED AZOLE DERIVATIVES AS THERAPEUTIC AGENTS TRANSTECH PHARMA INC (US) 2005-10-13 — — WO disclosed
US-20050187277-A1 Substituted azole derivatives, compositions, and methods of use TRANSTECH PHARMA, INC. 2005-08-25 — — US disclosed
US-20040192743-A1 Substituted azole derivatives as therapeutic agents TRANSTECH PHARMA, INC. 2004-09-30 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040192743-A1 Substituted azole derivatives as therapeutic agents PTPRS, PTPRO, PTPRJ SMN1; SMN2 4575/4885KDM4E 672/4885NPC1 3792/4885
US-20110092553-A1 Substituted Azole Derivatives, Compositions, and Methods of Use PTPRO, PTPN5, PTPRE SMN1; SMN2 4417/4885KDM4E 733/4885NPC1 3228/4885
US-20050187277-A1 Substituted azole derivatives, compositions, and methods of use PTPRO, PTPN5, PTPRE SMN1; SMN2 4417/4885KDM4E 733/4885NPC1 3228/4885
US-20110077399-A1 Substituted Azole Derivatives as Therapeutic Agents PTPRS, PTPRO, PTPRJ SMN1; SMN2 4575/4885KDM4E 672/4885NPC1 3792/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.